Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • FDA promotes the development of generic versions of abuse-deterrent opioid analgesics

    by
    • Optum Workers' Comp
    | Dec 19, 2017
    Tag Icon
    Generics, Opioids, FDA
    The U.S. Food and Drug Administration (FDA) has approved ten opioid analgesics with abuse-deterrent formulations (ADFs) to date. Opioid analgesics with ADFs are designed to make certain types of abuse, such as crushing a tablet to snort or dissolving a capsule to inject, more difficult or less rewarding. However, according to the Institute for Clinical and Economic Review (ICER) report “Abuse-Deterrent Opioids: Effectiveness and Value” published in August, only one opioid, OxyContin® (oxycodone extended-release), demonstrated sufficient evidence to suggest a reduced risk of abuse compared to non-ADF opioid analgesics.


  • Optum awarded NCQA 3-Year Case Management Accreditation

    by
    • Optum Workers' Comp
    | Dec 15, 2017
    Tag Icon
    Workers' Compensation
    We’re proud to announce that the Optum Case Management program received certification from the National Committee for Quality Assurance (NCQA). Recognized for quality, the NCQA reviewed our policies, procedures and data reporting and awarded us the highest level of accreditation—a 3 year accreditation—for our comprehensive case management program.


  • Final approval of the California workers’ compensation MTUS drug formulary

    by
    • Optum Workers' Comp
    | Dec 13, 2017
    Tag Icon
    formulary
    The California Office of Administrative Law has approved the final MTUS Drug Formulary regulations submitted by the Division of Workers’ Compensation (DWC) fully adopting a workers’ compensation drug formulary. The formulary and related rules will go into effect January 1, 2018.


  • FDA approves new device for opioid withdrawal symptoms

    by
    • Optum Workers' Comp
    | Dec 13, 2017
    Tag Icon
    Opioids, FDA
    An electrical stimulation device has been granted an indication from the U.S. Food and Administration (FDA) for reducing opioid withdrawal symptoms. The FDA’s rapid expansion of the new indication for this device demonstrates its commitment to support novel ways to assist those who have been afflicted by opioid addiction.